{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:28:36Z","timestamp":1791919716478,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T00:00:00Z","timestamp":1716076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T00:00:00Z","timestamp":1716076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008126","name":"Jeju National University Hospital","doi-asserted-by":"publisher","award":["JUNH2021"],"award-info":[{"award-number":["JUNH2021"]}],"id":[{"id":"10.13039\/501100008126","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>HER2<\/jats:italic>\n                    amplification-associated molecular alterations and clinicopathologic features in colorectal cancers (CRCs) have not been well established. In this study, we assessed the prevalence of\n                    <jats:italic>HER2<\/jats:italic>\n                    amplification and microsatellite instability (MSI) status of 992 patients with primary CRC. In addition, molecular alterations of\n                    <jats:italic>HER2<\/jats:italic>\n                    amplified and unamplified CRCs were examined and compared by next-generation sequencing.\n                    <jats:italic>HER2<\/jats:italic>\n                    amplifications were found in 41 (4.1%) of 992 primary CRCs.\n                    <jats:italic>HER2<\/jats:italic>\n                    amplification was identified in 1.0% of the right colonic tumors, 5.1% of the left colonic tumors, and 4.8% of the rectal tumors. Approximately 95% of\n                    <jats:italic>HER2<\/jats:italic>\n                    amplification was observed in the left colon and rectum. Seven (87.5%) of eight metastatic tumors showed\n                    <jats:italic>HER2<\/jats:italic>\n                    amplification. Most clinicopathologic features were unrelated to\n                    <jats:italic>HER2<\/jats:italic>\n                    amplification except tumor size and MSI status. All 41\n                    <jats:italic>HER2<\/jats:italic>\n                    amplified CRCs were microsatellite stable. In a molecular analysis of frequently identified somatic mutations in CRCs,\n                    <jats:italic>HER2<\/jats:italic>\n                    amplified CRCs showed a lower rate of\n                    <jats:italic>KRAS<\/jats:italic>\n                    mutations (24.4%) but a higher rate of\n                    <jats:italic>TP53<\/jats:italic>\n                    mutations (83%) than unamplified CRCs. No\n                    <jats:italic>BRAF<\/jats:italic>\n                    and\n                    <jats:italic>NRAS<\/jats:italic>\n                    mutations were identified in\n                    <jats:italic>HER2<\/jats:italic>\n                    amplified CRCs. Our study suggests that\n                    <jats:italic>HER2<\/jats:italic>\n                    amplified CRCs are mutually exclusive of MSI and harbor less frequent\n                    <jats:italic>KRAS\/NRAS\/BRAF<\/jats:italic>\n                    mutations but frequent\n                    <jats:italic>T53<\/jats:italic>\n                    mutations.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-62096-x","type":"journal-article","created":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T14:01:18Z","timestamp":1716127278000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["RAS\/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification"],"prefix":"10.1038","volume":"14","author":[{"given":"Sun Mi","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjoo","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,19]]},"reference":[{"key":"62096_CR1","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/path.4679","volume":"238","author":"SD Richman","year":"2016","unstructured":"Richman, S. D. et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: Analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J. Pathol. 238, 562\u2013570. https:\/\/doi.org\/10.1002\/path.4679 (2016).","journal-title":"J. Pathol."},{"key":"62096_CR2","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.humpath.2010.02.018","volume":"41","author":"AH Marx","year":"2010","unstructured":"Marx, A. H. et al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum. Pathol. 41, 1577\u20131585. https:\/\/doi.org\/10.1016\/j.humpath.2010.02.018 (2010).","journal-title":"Hum. Pathol."},{"key":"62096_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098528","volume":"9","author":"AN Seo","year":"2014","unstructured":"Seo, A. N. et al. HER2 status in colorectal cancer: Its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One 9, e98528. https:\/\/doi.org\/10.1371\/journal.pone.0098528 (2014).","journal-title":"PLoS One"},{"key":"62096_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11745-011-3649-7","volume":"47","author":"N Li","year":"2012","unstructured":"Li, N., Bu, X., Wu, P., Wu, P. & Huang, P. The, \u201cHER2-PI3K\/Akt-FASN Axis\u201d regulated malignant phenotype of colorectal cancer cells. Lipids 47, 403\u2013411. https:\/\/doi.org\/10.1007\/s11745-011-3649-7 (2012).","journal-title":"Lipids"},{"key":"62096_CR5","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1158\/1078-0432.CCR-23-1041","volume":"29","author":"SJ Casak","year":"2023","unstructured":"Casak, S. J. et al. FDA approval summary: Tucatinib with trastuzumab for advanced unresectable or metastatic, chemotherapy refractory, HER2-positive RAS wild-type colorectal cancer. Clin. Cancer Res. 29, 4326\u20134330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1041 (2023).","journal-title":"Clin. Cancer Res."},{"key":"62096_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2478\/raon-2019-0033","volume":"53","author":"VA Afrasanie","year":"2019","unstructured":"Afrasanie, V. A. et al. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer\u2014Practical implications for the clinician. Radiol. Oncol. 53, 265\u2013274. https:\/\/doi.org\/10.2478\/raon-2019-0033 (2019).","journal-title":"Radiol. Oncol."},{"key":"62096_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/cncr.20337","volume":"101","author":"D Alexander","year":"2004","unstructured":"Alexander, D. et al. Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma. Cancer 101, 66\u201376. https:\/\/doi.org\/10.1002\/cncr.20337 (2004).","journal-title":"Cancer"},{"key":"62096_CR8","doi-asserted-by":"publisher","first-page":"42198","DOI":"10.18632\/oncotarget.15030","volume":"8","author":"J Gong","year":"2017","unstructured":"Gong, J., Cho, M., Sy, M., Salgia, R. & Fakih, M. Molecular profiling of metastatic colorectal tumors using next-generation sequencing: A single-institution experience. Oncotarget 8, 42198\u201342213. https:\/\/doi.org\/10.18632\/oncotarget.15030 (2017).","journal-title":"Oncotarget"},{"key":"62096_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.21037\/jgo-21-47","volume":"12","author":"H Huang","year":"2021","unstructured":"Huang, H., Wang, Z., Li, Y., Zhao, Q. & Niu, Z. Amplification of the human epidermal growth factor receptor 2 (HER2) gene is associated with a microsatellite stable status in Chinese gastric cancer patients. J. Gastrointest. Oncol. 12, 377\u2013387. https:\/\/doi.org\/10.21037\/jgo-21-47 (2021).","journal-title":"J. Gastrointest. Oncol."},{"key":"62096_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson, A. B. et al. Colon Cancer, Version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 19, 329\u2013359. https:\/\/doi.org\/10.6004\/jnccn.2021.0012 (2021).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"62096_CR11","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1038\/bjc.2014.483","volume":"111","author":"B Ingold Heppner","year":"2014","unstructured":"Ingold Heppner, B. et al. HER2\/neu testing in primary colorectal carcinoma. Br. J. Cancer 111, 1977\u20131984. https:\/\/doi.org\/10.1038\/bjc.2014.483 (2014).","journal-title":"Br. J. Cancer"},{"key":"62096_CR12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","volume":"25","author":"E Missiaglia","year":"2014","unstructured":"Missiaglia, E. et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann. Oncol. 25, 1995\u20132001. https:\/\/doi.org\/10.1093\/annonc\/mdu275 (2014).","journal-title":"Ann. Oncol."},{"key":"62096_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13000-015-0380-3","volume":"10","author":"SW Wu","year":"2015","unstructured":"Wu, S. W., Ma, C. C. & Li, W. H. Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis. Diagn. Pathol. 10, 144. https:\/\/doi.org\/10.1186\/s13000-015-0380-3 (2015).","journal-title":"Diagn. Pathol."},{"key":"62096_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5009\/gnl.2014.8.1.13","volume":"8","author":"IY Shin","year":"2014","unstructured":"Shin, I. Y. et al. The expression of multiple proteins as prognostic factors in colorectal cancer: Cathepsin D, p53, COX-2, epidermal growth factor receptor, C-erbB-2, and Ki-67. Gut Liver 8, 13\u201323. https:\/\/doi.org\/10.5009\/gnl.2014.8.1.13 (2014).","journal-title":"Gut Liver"},{"key":"62096_CR15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/sj.bjc.6600127","volume":"86","author":"JA McKay","year":"2002","unstructured":"McKay, J. A. et al. c-erbB-2 is not a major factor in the development of colorectal cancer. Br. J. Cancer 86, 568\u2013573. https:\/\/doi.org\/10.1038\/sj.bjc.6600127 (2002).","journal-title":"Br. J. Cancer"},{"key":"62096_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"Cancer Genome Atlas Nature","year":"2012","unstructured":"Cancer Genome Atlas Nature. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330\u2013337. https:\/\/doi.org\/10.1038\/nature11252 (2012).","journal-title":"Nature"},{"key":"62096_CR17","doi-asserted-by":"publisher","first-page":"86356","DOI":"10.18632\/oncotarget.21169","volume":"8","author":"ME Salem","year":"2017","unstructured":"Salem, M. E. et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget 8, 86356\u201386368. https:\/\/doi.org\/10.18632\/oncotarget.21169 (2017).","journal-title":"Oncotarget"},{"key":"62096_CR18","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00384-009-0702-6","volume":"24","author":"G Baiocchi","year":"2009","unstructured":"Baiocchi, G. et al. ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int. J. Colorectal Dis. 24, 1059\u20131068. https:\/\/doi.org\/10.1007\/s00384-009-0702-6 (2009).","journal-title":"Int. J. Colorectal Dis."},{"key":"62096_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3233\/CBM-2012-00282","volume":"11","author":"Y Lu","year":"2012","unstructured":"Lu, Y. et al. Expression of EGFR, HER2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer. Cancer Biomark. 11, 219\u2013226. https:\/\/doi.org\/10.3233\/CBM-2012-00282 (2012).","journal-title":"Cancer Biomark."},{"key":"62096_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-9-1","volume":"9","author":"DO Kavanagh","year":"2009","unstructured":"Kavanagh, D. O. et al. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?. BMC Cancer 9, 1. https:\/\/doi.org\/10.1186\/1471-2407-9-1 (2009).","journal-title":"BMC Cancer"},{"key":"62096_CR21","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","volume":"20","author":"F Meric-Bernstam","year":"2019","unstructured":"Meric-Bernstam, F. et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 20, 518\u2013530. https:\/\/doi.org\/10.1016\/S1470-2045(18)30904-5 (2019).","journal-title":"Lancet Oncol."},{"key":"62096_CR22","doi-asserted-by":"publisher","first-page":"e1671","DOI":"10.1634\/theoncologist.2020-0356","volume":"25","author":"Y Guo","year":"2020","unstructured":"Guo, Y. et al. Genomic alterations of NTRK, POLE, ERBB2, and microsatellite instability status in Chinese patients with colorectal cancer. Oncologist 25, e1671\u2013e1680. https:\/\/doi.org\/10.1634\/theoncologist.2020-0356 (2020).","journal-title":"Oncologist"},{"key":"62096_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.clcc.2022.01.009","volume":"21","author":"C Sun","year":"2022","unstructured":"Sun, C. et al. Treatment of advanced BRAF-mutated colorectal cancer: Where we are and where we are going. Clin. Colorectal Cancer 21, 71\u201379. https:\/\/doi.org\/10.1016\/j.clcc.2022.01.009 (2022).","journal-title":"Clin. Colorectal Cancer"},{"key":"62096_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.602596","volume":"11","author":"G Rosati","year":"2021","unstructured":"Rosati, G., Aprile, G., Basile, D. & Avallone, A. Perspectives in the treatment of RAS or BRAF mutated metastatic colorectal cancer patients. Front. Oncol. 11, 602596. https:\/\/doi.org\/10.3389\/fonc.2021.602596 (2021).","journal-title":"Front. Oncol."},{"key":"62096_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","volume":"2","author":"RB Corcoran","year":"2012","unstructured":"Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227\u2013235. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0341 (2012).","journal-title":"Cancer Discov."},{"key":"62096_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ejca.2015.01.054","volume":"51","author":"F Pietrantonio","year":"2015","unstructured":"Pietrantonio, F. et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. Eur. J. Cancer 51, 587\u2013594. https:\/\/doi.org\/10.1016\/j.ejca.2015.01.054 (2015).","journal-title":"Eur. J. Cancer"},{"key":"62096_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/carcin\/bgm228","volume":"29","author":"K Imai","year":"2008","unstructured":"Imai, K. & Yamamoto, H. Carcinogenesis and microsatellite instability: The interrelationship between genetics and epigenetics. Carcinogenesis 29, 673\u2013680. https:\/\/doi.org\/10.1093\/carcin\/bgm228 (2008).","journal-title":"Carcinogenesis"},{"key":"62096_CR28","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1463-1318.2007.01378.x","volume":"10","author":"LH Jensen","year":"2008","unstructured":"Jensen, L. H., Lindebjerg, J., Byriel, L., Kolvraa, S. & Cruger, D. G. Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency. Colorectal Dis. 10, 490\u2013497. https:\/\/doi.org\/10.1111\/j.1463-1318.2007.01378.x (2008).","journal-title":"Colorectal Dis."},{"key":"62096_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14740\/gr1239","volume":"13","author":"M Ahmed","year":"2020","unstructured":"Ahmed, M. Colon cancer: A clinician\u2019s perspective in 2019. Gastroenterol. Res. 13, 1\u201310. https:\/\/doi.org\/10.14740\/gr1239 (2020).","journal-title":"Gastroenterol. Res."},{"key":"62096_CR30","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior, I. A., Hood, F. E. & Hartley, J. L. The frequency of RAS mutations in cancer. Cancer Res. 80, 2969\u20132974. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3682 (2020).","journal-title":"Cancer Res."},{"key":"62096_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084120","author":"F Negri","year":"2022","unstructured":"Negri, F., Bottarelli, L., de\u2019Angelis, G. L. & Gnetti, L. KRAS: A druggable target in colon cancer patients. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms23084120 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"62096_CR32","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3322\/caac.21728","volume":"72","author":"F Ciardiello","year":"2022","unstructured":"Ciardiello, F. et al. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J. Clin. 72, 372\u2013401. https:\/\/doi.org\/10.3322\/caac.21728 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"62096_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/ijc.28955","volume":"136","author":"M Schirripa","year":"2015","unstructured":"Schirripa, M. et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int. J. Cancer 136, 83\u201390. https:\/\/doi.org\/10.1002\/ijc.28955 (2015).","journal-title":"Int. J. Cancer"},{"key":"62096_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00226","volume":"3","author":"K Raghav","year":"2019","unstructured":"Raghav, K. et al. Validation of HER2 amplification as a predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precis. Oncol. 3, 1\u201313. https:\/\/doi.org\/10.1200\/PO.18.00226 (2019).","journal-title":"JCO Precis. Oncol."},{"key":"62096_CR35","doi-asserted-by":"publisher","first-page":"567","DOI":"10.6004\/jnccn.2023.5012","volume":"21","author":"M Malla","year":"2023","unstructured":"Malla, M., Pedersen, K. S. & Parikh, A. R. Updates in the treatment of metastatic colorectal cancer. J. Natl. Compr. Cancer Netw. 21, 567\u2013571. https:\/\/doi.org\/10.6004\/jnccn.2023.5012 (2023).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"62096_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/jmcb\/mjy075","volume":"11","author":"M Nakayama","year":"2019","unstructured":"Nakayama, M. & Oshima, M. Mutant p53 in colon cancer. J. Mol. Cell Biol. 11, 267\u2013276. https:\/\/doi.org\/10.1093\/jmcb\/mjy075 (2019).","journal-title":"J. Mol. Cell Biol."},{"key":"62096_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/humu.10175","volume":"21","author":"B Iacopetta","year":"2003","unstructured":"Iacopetta, B. TP53 mutation in colorectal cancer. Hum. Mutat. 21, 271\u2013276. https:\/\/doi.org\/10.1002\/humu.10175 (2003).","journal-title":"Hum. Mutat."},{"key":"62096_CR38","doi-asserted-by":"publisher","first-page":"7518","DOI":"10.1200\/JCO.2005.00.471","volume":"23","author":"A Russo","year":"2005","unstructured":"Russo, A. et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: Influence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol. 23, 7518\u20137528. https:\/\/doi.org\/10.1200\/JCO.2005.00.471 (2005).","journal-title":"J. Clin. Oncol."},{"key":"62096_CR39","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nature10933","volume":"486","author":"SP Shah","year":"2012","unstructured":"Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395\u2013399. https:\/\/doi.org\/10.1038\/nature10933 (2012).","journal-title":"Nature"},{"key":"62096_CR40","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1158\/1078-0432.CCR-13-2943","volume":"20","author":"L Silwal-Pandit","year":"2014","unstructured":"Silwal-Pandit, L. et al. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin. Cancer Res. 20, 3569\u20133580. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2943 (2014).","journal-title":"Clin. Cancer Res."},{"key":"62096_CR41","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a001008","volume":"2","author":"M Olivier","year":"2010","unstructured":"Olivier, M., Hollstein, M. & Hainaut, P. TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb Perspect. Biol. 2, a001008. https:\/\/doi.org\/10.1101\/cshperspect.a001008 (2010).","journal-title":"Cold Spring Harb Perspect. Biol."},{"key":"62096_CR42","first-page":"251","volume-title":"AJCC Cancer Staging Manual","author":"JM Jessup","year":"2017","unstructured":"Jessup, J. M. et al. Colon and Rectum. In AJCC Cancer Staging Manual 8th edn (eds Amin, M. et al.) 251\u2013274 (Springer Nature, 2017).","edition":"8"},{"key":"62096_CR43","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","volume":"52","author":"M Hofmann","year":"2008","unstructured":"Hofmann, M. et al. Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology 52, 797\u2013805. https:\/\/doi.org\/10.1111\/j.1365-2559.2008.03028.x (2008).","journal-title":"Histopathology"},{"key":"62096_CR44","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/modpathol.2011.198","volume":"25","author":"J Ruschoff","year":"2012","unstructured":"Ruschoff, J. et al. HER2 testing in gastric cancer: A practical approach. Mod. Pathol. 25, 637\u2013650. https:\/\/doi.org\/10.1038\/modpathol.2011.198 (2012).","journal-title":"Mod. Pathol."},{"key":"62096_CR45","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25, 1754\u20131760. https:\/\/doi.org\/10.1093\/bioinformatics\/btp324 (2009).","journal-title":"Bioinformatics"},{"key":"62096_CR46","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The genome analysis toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303. https:\/\/doi.org\/10.1101\/gr.107524.110 (2010).","journal-title":"Genome Res."},{"key":"62096_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fgene.2012.00035","volume":"3","author":"P Cingolani","year":"2012","unstructured":"Cingolani, P. et al. Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift. Front. Genet. 3, 35. https:\/\/doi.org\/10.3389\/fgene.2012.00035 (2012).","journal-title":"Front. Genet."},{"key":"62096_CR48","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/humu.22932","volume":"37","author":"X Liu","year":"2016","unstructured":"Liu, X., Wu, C., Li, C. & Boerwinkle, E. dbNSFP v30: A one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs. Hum. Mutat. 37, 235\u2013241. https:\/\/doi.org\/10.1002\/humu.22932 (2016).","journal-title":"Hum. Mutat."},{"key":"62096_CR49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326. https:\/\/doi.org\/10.1038\/nbt.1754 (2011).","journal-title":"Nat. Biotechnol."},{"key":"62096_CR50","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/cncr.31125","volume":"124","author":"JS Ross","year":"2018","unstructured":"Ross, J. S. et al. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer 124, 1358\u20131373. https:\/\/doi.org\/10.1002\/cncr.31125 (2018).","journal-title":"Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62096-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62096-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62096-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T14:01:50Z","timestamp":1716127310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62096-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,19]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["62096"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-62096-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,19]]},"assertion":[{"value":"29 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11432"}}